RNAi Technologies and Global Markets: BIO127B

Library

Username

Password

Remember Me

Forgot password/Login issues?

Not a Member? Learn more.

Report Highlights

The global market for RNA Interference technologies is expected to grow from $262.1 million in 2015 to $392.6 million in 2020, registering a compound annual growth rate (CAGR) of 8.4%.

Report Includes

An overview of the global market for RNAi technologies which are used in the areas of drug delivery, therapeutics, and diagnostics
Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
A breakdown of the technologies: RNAi for drug delivery (by nanoparticle delivery, nucleic acid delivery, aptamer delivery); RNAi for drug discovery and therapeutics (by diseases); RNAi for disease diagnostics and biomarker development (by diseases); and RNAi for reagents, research tools, and other applications (by application)
Examination of significant deals in the RNAi technologies sector during the last decade
A look at commercial opportunities in the RNAi research tools and reagents, drug development, diagnostic, and agriculture markets
Profiles of major players in the industry

Report Scope

BCC Research conducted the market assessment, the global and regional breakdown of sales data, market projection for the commercial RNAi technologies, application of the techniques in commercial sector as well as in research and development. Further, BCC Research offers the details of new developments, patent analysis, market leaders and market share, etc. for the RNAi technologies and its applications.

The report summarizes the global RNAi technologies market by category and by region. The RNAi market is analyzed based on RNAi research tools and reagents as well as on RNAi diagnostics. The research tools and reagents and therapeutics considered in this report are mainly for small/short interfering RNAs (siRNAs) and diagnostics are mainly based on microRNAs (miRNAs).

MicroRNA (miRNA) research tools, services, drug discovery etc. are excluded from this report; however, these areas are worth a separate report and thus are analyzed in BCC Research report BIO115B in detail. U.S. and non-U.S. markets are considered for the geographical market analysis. The prospective application of RNAi therapeutics in various disease classifications such as oncological, cardiovascular, neurodegenerative, ophthalmologic and others are discussed. The application and progress of RNAi technologies in agriculture is also discussed in this report.

BCC Research verified the sales data for the global and regional RNAi markets for the present and projected values through statistical analysis. The tools/technology details in the report are based on their present and their prospective application and suitability.

Frequently Asked Questions (FAQs)

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com

[+] Show Chapter Details

.	Title/Chapter Name	Pages	Price	Member Price
RNAi Technologies and Global Markets	Full Report: RNAi Technologies and Global Markets	176	$2,750	Free
INTRODUCTION	Chapter- 1: INTRODUCTION	4		Free
STUDY OBJECTIVES REASONS FOR DOING THIS STUDY CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE SCOPE OF THE STUDY METHODOLOGY INFORMATION SOURCES ANALYST CREDENTIALS RELATED BCC RESEARCH REPORTS BCC RESEARCH WEBSITE DISCLAIMER
EXECUTIVE SUMMARY	Chapter- 2: EXECUTIVE SUMMARY	2	$250	Free
Table Summary : GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020 Figure Summary : GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020
OVERVIEW	Chapter- 3: OVERVIEW	28	$438	Free
RIBONUCLEIC ACID (RNA) RNA INTERFERENCE (RNAI) RNA INTERFERENCE DRUG DELIVERY RNAI DRUG DISCOVERY AND DEVELOPMENT OTHER POTENTIAL APPLICATIONS OF RNA INTERFERENCE
NEW DEVELOPMENTS AND REGULATORY ACTIVITY	Chapter- 4: NEW DEVELOPMENTS AND REGULATORY ACTIVITY	8	$125	Free
NEW DEVELOPMENTS REGULATORY ASPECTS COLLABORATIVE TRIALS AND FUTURE ACTIVITIES
MARKET ANALYSIS	Chapter- 5: MARKET ANALYSIS	53	$828	Free
MARKET BY TECHNOLOGY MARKET BY REGION
INDUSTRY STRUCTURE	Chapter- 6: INDUSTRY STRUCTURE	9	$141	Free
RNAI RESEARCH TOOLS AND REAGENTS RNAI DIAGNOSTICS
PATENT ANALYSIS	Chapter- 7: PATENT ANALYSIS	9	$141	Free
PATENTS BY YEAR PATENTS BY COUNTRY FOR RNA INTERFERENCE TECHNOLOGIES PATENTS BY COMPANY FOR RNA INTERFERENCE TECHNOLOGIES PATENTS BY ASSIGNEE FOR RNA INTERFERENCE TECHNOLOGIES
CURRENT STATUS	Chapter- 8: CURRENT STATUS	22	$344	Free
INNOVATIVE TECHNOLOGIES AND PLATFORMS FOR RNA INTERFERENCE FACTORS AFFECTING THE RNA INTERFERENCE MARKET CURRENT DRIVERS FOR THE RNA INTERFERENCE TECHNOLOGY MARKET MERGER AND ACQUISITION ACTIVITIES FUNDING FOR DEVELOPMENT OF RNA INTERFERENCE THERAPEUTICS AND TECHNOLOGIES
COMPANY PROFILES	Chapter- 9: COMPANY PROFILES	36	$563	Free
ADVIRNA ALNYLAM PHARMACEUTICALS, INC. APEIRON BIOLOGICS AG APPLIED BIOLOGICAL MATERIALS, INC. ARBUTUS BIOPHARMA CORP. (PREVIOUSLY TEKMIRA PHARMACEUTICALS CORP.) ARCTURUS THERAPEUTICS, INC. ARROWHEAD RESEARCH CORP. ASCLETIS INC. BENITEC BIOPHARMA LTD. BIOGEN IDEC, INC. BIOMICS BIOTECHNOLOGIES CO. LTD. BIONEER CORP. CELLECTA, INC. CERULEAN PHARMA, INC. DICERNA PHARMACEUTICALS, INC. EXIQON A/S F. HOFFMANN-LA ROCHE AG (ROCHE) GENERAL ELECTRIC CO. INTEGRATED DNA TECHNOLOGIES, INC. INVIVOGEN ISIS PHARMACEUTICALS, INC. MARINA BIOTECH, INC. MODERNA THERAPEUTICS MONSANTO CO. NITTO DENKO CORP. PEPTIMED INC. QIAGEN N.V. QUARK PHARMACEUTICALS, INC. REGULUS THERAPEUTICS ROSETTA GENOMICS LTD. RXI PHARMACEUTICALS CORP. SANOFI SIGMA-ALDRICH SILENCE THERAPEUTICS PLC. SILENSEED LTD. SOLSTICE BIOLOGICS SOMAGENICS, INC. SUMITOMO DAINIPPON PHARMA CO. LTD. SYNGENTA INTERNATIONAL AG THE NATIONAL INSTITUTES OF HEALTH (NIH) THE RNAI CONSORTIUM AT BROAD INSTITUTE OF MIT AND HARVARD THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER THERMO FISHER SCIENTIFIC, INC. ZELTIA GROUP
APPENDIX	Chapter- 10: APPENDIX	5	$78	Free
GLOSSARY AND ABBREVIATIONS

Published - Oct-2013| Analyst - Faqing Yuan| Code - BIO127A

Report Highlights

The global RNAi research tool and reagent, therapeutic, diagnostic, and agriculture market was valued at $210.2 million in 2012. The RNAi market is expected to reach $220.3 million in 2013 and $290 million by 2018, with a compound annual growth rate (CAGR) of 5.7% for the period of 2013 to 2018.

Report Includes

An overview of the global market for RNAi technologies which are used in the areas of drug delivery, therapeutics, and diagnostics.
Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 to 2018.
A breakdown of the technologies: RNAi for drug delivery (by nanoparticle delivery, nucleic acid delivery, aptamer delivery); RNAi for drug discovery and therapeutics (by diseases); RNAi for disease diagnostics and biomarker development (by diseases); and RNAi for reagents, research tools, and other applications (by application).
Examination of significant deals in the RNAi technologies sector during the last decade.
Comprehensive company profiles of major players in the market.